bioinformatics
(55)
Imagene Labs
Imagene Labs is a Singapore-based health-tech company that runs an enterprise-grade, cloud-based B2B genetic analytics platform. Using patented ancestry-based genetic risk analytics and ethnically-relevant reference datasets, it turns a simple saliva sample into DNA insights that fitness, beauty, nutrition and healthcare brands use to build personalized products and services. Its consumer-facing brand, Ori, packages these insights into fitness, skincare and nutrition DNA tests for the Asian market and beyond.
Daehwan Kim
Daehwan Kim is a computational biologist and software engineer whose genome-alignment tools - TopHat, HISAT and HISAT2 - are cited more than 78,000 times and are used by researchers worldwide to read DNA and RNA data. A former Michael L. Rosenberg Assistant Professor in the Lyda Hill Department of Bioinformatics at UT Southwestern Medical Center, he co-founded Omphalos Lifesciences, where he invented L++, a high-level programming language meant to describe living systems the way C++ describes machines. His goal is a fully programmable, simulatable virtual cell.
Biotia
Biotia is a New York-based health-tech company that fights infectious diseases by combining next-generation DNA sequencing with AI-driven software. Its metagenomic platform identifies bacteria, fungi, parasites and viruses - plus antimicrobial-resistance markers - from a single sample against a curated database of more than 16,000 microbial species. Spun out of the Jacobs Technion-Cornell Institute at Cornell Tech and operating a CLIA-certified lab in New York City, Biotia turns a single microbiome test into an actionable clinical report to help providers diagnose hard-to-detect infections and support pathogen surveillance from the hospital to outer space.
BostonGene
BostonGene is a Waltham, Massachusetts biotechnology company that applies AI-driven multiomics to cancer. Its Tumor Portrait platform integrates DNA and RNA sequencing with immune and tumor-microenvironment analysis into a single test, producing molecular profiles that help oncologists select therapies and help pharmaceutical partners design trials, identify biomarkers, and accelerate drug development. Founded in 2015 and led by CEO Andrew Feinberg, the company reached unicorn status in 2022.
Code Ocean
Code Ocean is a New York-based B2B SaaS platform that makes computational research reproducible, traceable and collaborative. Its flagship Compute Capsule bundles code, data and the exact software environment together so an analysis runs identically today or years from now. Used by pharma, biotech and leading research institutes, and integrated with journals like Nature and IEEE, Code Ocean is building a trusted virtual lab where both scientists and AI agents can run real analyses with full version control, lineage and compliance.
Embleema
Embleema is a New York- and France-based healthcare technology company that builds a unified real-world data and evidence platform for clinical research. It aggregates clinical, genomic, and patient-reported data from electronic medical records, wearables, biospecimens, and patient apps into regulatory-grade datasets, and uses no-code protocol tools plus dynamic consent to help pharmaceutical sponsors, research sites, and patient groups run non-interventional and Phase IV studies faster and at lower cost. Founded in 2017 by Robert Chu, the company started with a patient-driven health blockchain and its analytics stack has been used by the FDA for genomic regulatory review.
Form Bio
Form Bio is an Austin-based computational life sciences company that builds AI-driven software to speed up the design, characterization, and manufacturing of genetic medicines, especially adeno-associated virus (AAV) cell and gene therapies. Spun out of Colossal Biosciences in 2022 with a $30M Series A, its platform lets scientists model billions of therapeutic vector designs in silico to improve efficacy, safety, and manufacturability before ever entering the lab, targeting the manufacturing bottleneck that drives the majority of FDA rejections in the field.
Omphalos Lifesciences Inc
Omphalos Lifesciences is a Dallas-based biotech software company building a programmable virtual cell platform. Founded by computational biologist Daehwan Kim - creator of the widely used HISAT and TopHat sequencing tools - the company created L++, a high-level programming language that lets biologists describe, simulate, and visualize living systems the way software engineers write code. Its Life Designer platform aims to accelerate drug discovery, precision medicine, and biomanufacturing by running experiments in silico before they hit the lab bench.
Plex Research
Plex Research is a Cambridge, Massachusetts company building an AI-powered scientific intelligence platform for drug discovery. Its proprietary focal graph technology stitches billions of minimally processed experimental data points from genomics, proteomics, chemical biology and clinical sources into a queryable biomedical knowledge graph, then pairs it with large language models so scientists get evidence-backed answers in seconds - every result traceable to the underlying experiments. Trusted by 40+ pharma and biotech teams, Plex helps researchers identify and evaluate drug targets, uncover hidden pharmacology, and, through its AutoPlex agent, run autonomous multi-step research campaigns.
Complete Genomics
Complete Genomics is a San Jose-based life-science technology company and the Americas arm of MGI. Founded in 2005 as a pioneer of affordable whole-human-genome sequencing, it develops and sells next-generation sequencing instruments, reagents, and analysis software built on its proprietary PCR-free DNBSEQ (DNA nanoball) technology. The company aims to drive down the cost of sequencing - from the landmark $5,000 genome to sub-$100 - and supplies researchers, clinical labs, and biotech companies with a full workflow spanning sample prep, library construction, sequencing, and data analysis.
Karius
Karius is a Redwood City, California life-sciences company that turns a single blood draw into a broad infectious-disease diagnosis. Its flagship Karius Test uses microbial cell-free DNA (mcfDNA) sequencing, metagenomics and AI to detect more than 1,000 pathogens - bacteria, DNA viruses, fungi and parasites - often within a day of receiving a sample. Founded in 2014 out of Stephen Quake's lab at Stanford, the company aims to give clinicians a fast, non-invasive alternative to invasive biopsies and slow cultures, with a focus on the immunocompromised patients who need answers most urgently.
Allelica, Inc.
Allelica is a genomics software company building the tools that move polygenic risk scores (PRS) out of the research lab and into routine clinical care. Its cloud platform lets labs and health systems develop, validate, and apply PRS across multiple ancestries, and its clinical test AbsoluteDx combines rare-variant (monogenic) and genome-wide (polygenic) risk in a single report. The company's stated priority is equity - building risk scores that work for patients regardless of genetic ancestry - and its multi-ancestry coronary artery disease work was cited in the 2026 ACC/AHA cardiovascular prevention guidelines.
Cipherome, Inc.
Cipherome is a San Jose-based clinical genomics and bioinformatics company on a mission to find the drug that works for each individual. Its no-code platform COMPASS lets researchers transform, query, and analyze massive clinical and genomic datasets - like the 500,000-participant UK Biobank - without writing code, while its Xentinel platform uses explainable AI to predict and reduce adverse drug reactions. Backed by roughly $16-23M through a Series B, the 12-person team pairs Silicon Valley software with Seoul National University biomedical-informatics research.
Clear Labs
Clear Labs is a San Carlos, California genomics company that builds Clear Dx, a fully automated next-generation sequencing platform. It turns whole genome sequencing - normally a slow, expert-heavy lab process - into a push-button diagnostic used by food manufacturers and public health labs to detect pathogens like Salmonella and Listeria, characterize SARS-CoV-2 and TB, and identify bacteria and fungi from clinical specimens, often with next-day results.
CoA Nexus, Inc.
CoA Nexus, Inc. (formerly Srust, Inc.) is a Tokyo- and Menlo Park-based deep-tech HR startup that uses proprietary AI to read tens of millions of research papers and patents, visualize a scientist's real skills, and match R&D talent with companies - from university spinouts to large manufacturers. Its flagship platform, CoA Researcher, is billed as Japan's largest researcher-matching platform, supporting full-time roles and side work across biotech, chemistry, medical science and semiconductors. The company raised a roughly ¥300 million Series A in October 2025 to expand its global researcher database and go beyond the reach of conventional job ads.
Floré
Floré, built by San Diego biotech Sun Genomics, makes probiotics the slow way: you mail in a stool sample, an accredited lab reads the whole genome of your gut microbiome, and an algorithm trained on tens of thousands of prior formulations builds a supplement matched to the bacteria you actually carry. Founded in 2016 by former Illumina and LabCorp genomicist Sunny Jain, the company sells a subscription that re-tests and re-formulates over time, and has published peer-reviewed research pairing its precision synbiotics with gut and autism-spectrum outcomes.
Simon Adar
Simon Adar is the co-founder and CEO of Code Ocean, a New York-based platform that packages research code, data, and compute environments into reproducible 'compute capsules' so scientists can rerun each other's work without wrestling with dependencies. A hyperspectral imaging PhD from Tel Aviv University turned Cornell Tech Runway postdoc, he started the company after concluding that too much of his own research time went into trying, and failing, to rerun other people's code.
TeselaGen Biotechnology
TeselaGen Biotechnology builds an AI-powered, cloud-based operating system for biological R&D. Spun out of the Department of Energy's Joint BioEnergy Institute and founded by Stanford and Berkeley scientists, its platform - organized around the Design-Build-Test-Learn cycle with DESIGN, BUILD, TEST and DISCOVER modules - lets researchers design DNA libraries, generate lab-robot assembly protocols, capture experimental data and apply machine learning to converge on better biological products faster. Customers span industrial biotech, biopharma and academia, including Amgen, LanzaTech, Twist Bioscience, Arzeda and Stanford.
MetaCell
MetaCell is a life-science software company staffed by scientists and software engineers who turn messy neuroscience and biology data - microscopy, MRI, EEG, electrophysiology, biologically accurate simulations - into usable, shareable, enterprise-grade online tools. Founded by the trio behind the OpenWorm project, MetaCell builds custom scientific software, cloud workspaces, and data pipelines for pharma companies and top research institutions including Johnson & Johnson, Pfizer, Biogen, Eisai, the Allen Institute, the Chan Zuckerberg Initiative, and universities like Princeton, Yale, and UCL.
Salt AI
Salt AI is a Los Angeles contextual-AI company building a visual platform that lets regulated enterprises - especially life sciences and healthcare teams - orchestrate many AI models into governed, auditable workflows that run inside their own infrastructure. Founded in 2023 by former Myspace CTO Aber Whitcomb and Jim Benedetto, Salt lets biochemists and clinicians drag, drop, and chain models like AlphaFold2 (which Salt runs 22x faster), ProteinMPNN, and Chroma without writing code, turning months of pipeline engineering into weeks while keeping every prompt, weight, and response logged for compliance.
Sentieon
Sentieon builds ultra-fast, highly accurate software for analyzing DNA and RNA sequencing data. Its pipelines - DNAseq, DNAscope, TNseq, and TNscope - replace the open-source GATK workflow with matching or better accuracy while running many times faster on ordinary CPUs, no specialized hardware required. Founded in 2014 and based in the Bay Area, the company has won top honors in multiple precisionFDA and DREAM challenges, and its tools are used by pharma, clinical labs, sequencing platform makers, and genomics researchers worldwide to turn raw reads into trustworthy variant calls quickly and cheaply.
Shennon Biotechnologies
Shennon Biotechnologies is a San Francisco biotech turning immune-cell target discovery from a months-long slog into a same-day job. Its proprietary TCELERATOR platform fuses ultra-high-throughput microfluidics with AI to functionally profile millions of single immune cells in hours, pinpointing the rare T and B cells that recognize cancer antigens. Founded in 2021 by physicist-turned-founder Li Sun, the company is building a pipeline of validated targets for solid tumors and autoimmune disease, backed by a $13M seed round led by DCVC.
T-Cypher Bio
T-Cypher Bio is an Oxford, UK biotechnology company building a pipeline of TCR (T cell receptor) therapeutics for solid tumours and immune-mediated diseases. Spun out of Orbit Discovery in 2021 on technology licensed from the University of Oxford, it pairs a high-throughput, functional bead-display platform with immunopeptidomics, AI and bioinformatics to deconvolute vast T cell repertoires, find disease-specific targets, and identify potent, target-specific TCRs.
James Lu
James Lu is the co-founder and CEO of Helix, a population genomics company he helped launch in 2015 with Justin Kao and Scott Burke. An MD/PhD trained at Baylor College of Medicine with chemical engineering degrees from Stanford, Lu built his career at the intersection of machine learning, electronic health records, and genetics. He argues that the genome should sit alongside blood pressure and cholesterol as a core clinical input - the difference being that your genome never changes. Under his leadership Helix runs one of the largest clinical sequencing labs in the US and the Helix Research Network, and its GenoSphere dataset links more than 500,000 clinico-genomic records.
Jonathan Wang
Jonathan Wang is the co-founder and CEO of Watershed (Watershed Informatics / Watershed Bio), a Cambridge-based biocomputing platform that lets biologists run complex multi-omics analyses without writing code. An MIT computer scientist who once built a high-frequency trading hedge fund out of his dorm room, Wang co-founded Domeyard before pivoting to biology in 2019, applying the speed-obsessed engineering culture of quant finance to the sprawling data problem of modern drug discovery. Watershed raised a $14.5M Series A led by Canvas Ventures in 2023 and aims to become the dominant biocomputing platform for the world's scientists.
Louis Licamele
Louis Licamele, PhD is a computer scientist turned drug developer who serves as Chief Development Officer and EVP of Clinical and Data Science at Bloom Science, a San Diego biotech building microbiome-based, ketogenic-mimicking live biotherapeutics for obesity and neurological disease. A founding team member, he oversees biostatistics, clinical data management, and data-driven trial design for the company's lead candidate BL-001. He built his career at the intersection of data and medicine - a BS in biology and computer science from Georgetown, a PhD in computer science from the University of Maryland, and senior informatics and biometrics roles at Vanda Pharmaceuticals and REGENXBIO. He also runs The Licamele Group, advising healthcare companies on data science, AI, and regulatory strategy.
Marilyn Matz
Marilyn Matz is the CEO and co-founder of Paradigm4, the Waltham, Massachusetts company behind SciDB, an array-native computational database built for the tangled, multi-dimensional data of genomics, clinical research, and imaging. She launched it in 2010 with database legend and Turing Award laureate Mike Stonebraker to move his MIT research into the hands of working scientists. Decades earlier she left MIT to co-found Cognex, now a global machine-vision powerhouse, where she ran worldwide engineering and later a business unit. A two-time technical founder who codes the deep infrastructure and still sells to the customer, Matz has spent a career making impossibly large scientific data explorable, reproducible, and fast.
Jun Ye
Jun Ye is the co-founder, president and CEO of Sentieon, a Mountain View bioinformatics company whose variant-calling software has swept the precisionFDA Truth and Consistency Challenges. A Stanford-trained electrical engineer with more than 50 U.S. patents, he previously co-founded Brion Technologies (acquired by ASML in 2006) and Founton Technologies (acquired into Alibaba in 2012), and taught at Stanford as a consulting professor for fourteen years.
Eduardo Abeliuk
Eduardo Abeliuk is the founder and CEO of TeselaGen Biotechnology, a Silicon Valley company building AI agents and enterprise software for biological R&D. A Chilean-born physicist and electrical engineer with a Stanford PhD, he sits at the intersection of biology, artificial intelligence, and software - treating DNA as data and lab work as something that ought to be automated. Before biotech he built a Facebook app that hit a million users in weeks and an edtech platform across Latin America. He holds multiple US patents in computational biology and synthetic biology and his academic work has been cited more than a thousand times.
Michael Driscoll
Michael Driscoll is the co-founder and CEO of Rill Data, a company building fast, operational business intelligence dashboards on top of an embedded analytics engine. He previously co-founded Metamarkets, the ad-analytics firm whose internal database became the open-source project Apache Druid before Snap acquired the company in 2017. A bioinformatician turned serial entrepreneur, Driscoll began his career as a software engineer on the Human Genome Project, holds a PhD in Bioinformatics from Boston University and an AB from Harvard, and has spent three decades arguing that metrics, not tables or dashboards, are the real interface between data teams and the businesses they serve.